down arrow

Leap Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US52187K2006
USD
1.27
0.1 (8.55%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
LAVA Therapeutics NV
Molecular Templates, Inc.
MiNK Therapeutics, Inc.
MAIA Biotechnology, Inc.
Precision BioSciences, Inc.
SAB Biotherapeutics, Inc.
Passage Bio, Inc.
Portage Biotech, Inc.
Leap Therapeutics, Inc.
eFFECTOR Therapeutics, Inc.
Miromatrix Medical, Inc.
Why is Leap Therapeutics, Inc. ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
Icon
No Data Found
Is Leap Therapeutics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Leap Therapeutics, Inc.
-54.48%
-0.09
403.39%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-24.21%
EBIT Growth (5y)
-158.78%
EBIT to Interest (avg)
-56.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.54
Sales to Capital Employed (avg)
0.01
Tax Ratio
0.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
68.96%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.78
EV to EBIT
0.22
EV to EBITDA
0.22
EV to Capital Employed
1.40
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
626.53%
ROE (Latest)
-331.91%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company
DEBT-EQUITY RATIO (HY)

Lowest at -312.16 %

OPERATING PROFIT(Q)

Highest at USD -12.35 MM

PRE-TAX PROFIT(Q)

Highest at USD -12.12 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

NET PROFIT(Q)

Highest at USD -12.12 MM

-10What is not working for the Company
INTEREST(9M)

At USD 0.01 MM has Grown at inf%

OPERATING CASH FLOW(Y)

Lowest at USD -60.08 MM

ROCE(HY)

Lowest at -183.72%

CASH AND EQV(HY)

Lowest at USD 50.84 MM

Here's what is working for Leap Therapeutics, Inc.
Operating Profit
Highest at USD -12.35 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD -12.12 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Debt-Equity Ratio
Lowest at -312.16 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Profit
Highest at USD -12.12 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Leap Therapeutics, Inc.
Interest
At USD 0.01 MM has Grown at inf%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Cash Flow
Lowest at USD -60.08 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Cash and Eqv
Lowest at USD 50.84 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."